 |
|
|
 |
|
Tailored Treatment Boosts Kidney Cancer Survival
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 Patients with metastatic, low-risk cancer should get very aggressive treatment, because there's a good chance the therapy will benefit them. But patients with metastatic, high-risk cancer may choose to decline treatment, because they'll get little or no benefit from it.
"Our paper identifies, very precisely, which patients should get which therapies," Belldegrun said.
The study was published in the Nov. 1 issue of Cancer.
Text Continues Below

More information
The American Urological Association has more about kidney cancer.
Page: << Prev | 1 | 2
-- Robert Preidt
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 11/1/2008
|
 |

SOURCE: University of California, Los Angeles, news release, Nov. 1, 2008
|